ABSTRACT
INTRODUCTION The neurological complications of leukemia and lymphoma are extraordinarily diverse and often difficult to separate from the complications associated with their treatments. The challenge for the neurologist at the bedside, therefore, is to sort carefully through the likelihood of neurological disease as a direct effect of the leukemia and lymphoma on the basis of tumor type, contrasted with the likelihood of neurotoxicity on the basis of the agents and doses that may have been used in the treatment. This information, when logically ordered and compared with the neuroanatomical localization of the lesion in the individual patient, can lead to a likely diagnosis.
